Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 549Lung Neoplasms 312Small Cell Lung Carcinoma 87Colorectal Neoplasms 71Melanoma 68Breast Neoplasms 60Neoplasms 55Ovarian Neoplasms 47Neoplasm Metastasis 45Carcinoma, Renal Cell 45Squamous Cell Carcinoma of Head and Neck 43Pancreatic Neoplasms 39Stomach Neoplasms 37Triple Negative Breast Neoplasms 31Head and Neck Neoplasms 30Esophageal Neoplasms 28Endometrial Neoplasms 25Prostatic Neoplasms 24Uterine Cervical Neoplasms 23Urinary Bladder Neoplasms 23Brain Neoplasms 22Colonic Neoplasms 21Mesothelioma 20Mesothelioma, Malignant 18Carcinoma, Hepatocellular 18Sarcoma 16Carcinoma, Transitional Cell 15Adenocarcinoma of Lung 15Lung Diseases 14NSCLC 13

Interventions

pelcitoclax 1osimertinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × EGFR Positive Non-small Cell Lung Cancer × Thoracic × Clear all
NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
80 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡